i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal.
ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal.
J Nanobiotechnology. 2023 Oct 2;21(1):357. doi: 10.1186/s12951-023-02126-4.
Colorectal cancer (CRC) is one of the deadliest cancers worldwide, with the 5 year survival rate in metastatic cases limited to 12%. The design of targeted and effective therapeutics remains a major unmet clinical need in CRC treatment. Carcinoembryonic antigen (CEA), a glycoprotein overexpressed in most colorectal tumors, may constitute a promising molecule for generating novel CEA-targeted therapeutic strategies for CRC treatment. Here, we developed a smart nanoplatform based on chemical conjugation of an anti-CEA single-chain variable fragment (scFv), MFE-23, with PLGA-PEG polymers to deliver the standard 5-Fluorouracil (5-FU) chemotherapy to CRC cells. We confirmed the specificity of the developed CEA-targeted NPs on the internalization by CEA-expressing CRC cells, with an enhance of threefold in the cell uptake. Additionally, CEA-targeted NPs loaded with 5-FU induced higher cytotoxicity in CEA-expressing cells, after 24 h and 48 h of treatment, reinforcing the specificity of the targeted NPs. Lastly, the safety of CEA-targeted NPs loaded with 5-FU was evaluated in donor-isolated macrophages, with no relevant impact on their metabolic activity nor polarization. Altogether, this proof of concept supports the CEA-mediated internalization of targeted NPs as a promising chemotherapeutic strategy for further investigation in different CEA-associated cancers and respective metastatic sites.Authors: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 1 Given name: [Maria José] Last name [Silveira]. Author 7 Given name: [Maria José] Last name [Oliveira]. Also, kindly confirm the details in the metadata are correctokAffiliations: Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary.ok.
结直肠癌(CRC)是全球最致命的癌症之一,转移性病例的 5 年生存率仅为 12%。设计针对 CRC 的靶向且有效的治疗方法仍然是 CRC 治疗中一个重大的未满足的临床需求。癌胚抗原(CEA)是在大多数结直肠肿瘤中过度表达的糖蛋白,它可能构成一种有前途的分子,可用于开发针对 CRC 的新型 CEA 靶向治疗策略。在这里,我们通过化学偶联抗 CEA 单链可变片段(scFv)MFE-23 与 PLGA-PEG 聚合物,开发了一种基于智能纳米平台,以将标准的 5-氟尿嘧啶(5-FU)化疗药物递送至 CRC 细胞。我们证实了所开发的针对 CEA 的 NPs 在 CEA 表达的 CRC 细胞内化中的特异性,细胞摄取量增加了三倍。此外,载有 5-FU 的针对 CEA 的 NPs 在 CEA 表达细胞中诱导更高的细胞毒性,在治疗 24 小时和 48 小时后,强化了靶向 NPs 的特异性。最后,在供体分离的巨噬细胞中评估了载有 5-FU 的针对 CEA 的 NPs 的安全性,对其代谢活性和极化没有任何相关影响。总之,这个概念验证支持 CEA 介导的靶向 NPs 的内化是一种有前途的化疗策略,可在不同的 CEA 相关癌症及其各自的转移部位进一步研究。
作者:请确认作者姓名是否准确无误,并按正确的顺序(名、中间名/首字母、姓)呈现。作者 1 名:[玛丽亚·何塞]姓:[席尔瓦]。作者 7 名:[玛丽亚·何塞]姓:[奥利维拉]。此外,请检查并确认元数据中的详细信息是否正确。
ok
作者:请确认作者姓名是否准确无误,并按正确的顺序(名、中间名/首字母、姓)呈现。作者 1 名:[玛丽亚·何塞]姓:[席尔瓦]。作者 7 名:[玛丽亚·何塞]姓:[奥利维拉]。此外,请检查并确认元数据中的详细信息是否正确。
ok
Affiliations:请检查并确认作者及其各自的所属机构是否已正确识别,并在必要时进行更正。
ok
J Nanobiotechnology. 2023-10-2
J Pharmacol Exp Ther. 2019-1-22
J Biomater Sci Polym Ed. 2020-6
Eur J Nucl Med Mol Imaging. 2023-10
Anticancer Agents Med Chem. 2024
Front Bioeng Biotechnol. 2022-12-16
Eur J Med Chem. 2023-1-15
Int J Clin Exp Pathol. 2022-10-15
RSC Adv. 2021-3-3
Signal Transduct Target Ther. 2022-2-7